Trial Details

Recruiting
Basic Information
Clinical ID c5022
Identifier ISRCTN12358813
Trial Title Asp-PSC: effect of aspirin on reducing cancer & improving outcomes in primary sclerosing cholangitis
Trial URL Visit Original Page
Study Information
Study Results

Yes
Conditions Primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD) Digestive System
Interventions Participants will be randomised using OpenClinica and assigned treatment via Sealed Envelope. Each treatment group will receive either 75 mg aspirin or a placebo tablet to take once a day, orally for 5 years. All participants will be screened and have the
Participant Information
Sponsor Imperial College London
City NULL
Country/Region United Kingdom
Enrollment Criteria
Sex Requirement ALL
Age Requirement NULL
Study Design
Study Type Interventional
Phase PHASE3
Time Information
Start Date NULL
Primary Completion Date NULL
Completion Date NULL